$1,185.99
Closed
-(-)

At close

Financial advisor consultation illustration
Get professional financial guidance

Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply

About

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The company is headquartered in Indianapolis, Indiana and currently employs 50,000 full-time employees. The firm manufacture and distribute its products through facilities in the United States, including Puerto Rico, and in Europe and Asia. The Company’s products are sold in approximately 90 countries. Its Cardiometabolic Health products Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound, and others. Its oncology products include Cyramza, Erbitux, Tyvyt, Verzenio, Retevmo, Jaypirca, and others. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. Its LillyDirect, a direct-to-patient digital health care platform, provides delivery of select Lilly medicines dispensed by third-party pharmacies to patients.
Country

US

CEO

Mr. David Ricks

IPO date

1970

Employees

50,000

ISIN

US5324571083

Key stats

Open

$1.22K

Volume

2.10M

Market cap

$1.15T

Prev. close

$1.22K

Impl / hst vl

-

Open interest

$0.00

$1,178.32

Day’s Range

$1,226.60

$850.51

52W Range

$1,249.45

Valuation

44
Valuation score
Fairly Valued
P/E
45.52
P/S
15.93
P/B
36.88
Current ratio
1.50
Debt / Equity
1.22
ROE
101.31%
Gross margin
81.93%
Income growth
11.42%
FCF growth
1,002.68

Sep

10

Dividends

The next payment date will be Sep 10, 2026

Div. per Share

$1.73

Div. Yield

0.14%

Payout Ratio

-

Div. Growth YoY

0.00%

Analysts estimates

Consensus rating
Buy

The average rating from top 19 analysts indicates that stock is expected to perform in line with the market

Str. Sell
Sell
Hold
Buy
Str. Buy
Avg. price target
$1,236.52
The top 33 analysts forecasts that 12-month price may increase by 4.26%, with a low of $858.50 and a high of $1,575.00
$858.50
Low
$1,236.52
Avg
$1,575.00
High
Current price

Earnings

Q1 ‘26 revenue
$19.80B
Q1 ‘26 net income
$7.40B
Revenue
Net income
Previous EPS
$8.55
Estimate EPS
$8.89
Actual EPS
Estimate EPS
Financial advisor consultation illustration
Get professional financial guidance

Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply